CAR T细胞和T细胞偶联剂在肾移植术前脱敏治疗中的应用
CAR T cells and T cell engagers for desensitization in kidney transplantation
文章综述了CAR T细胞和T细胞偶联剂在肾移植术前脱敏治疗中的应用前景,讨论了治疗风险与移植生存率和生活质量的关系。
- Clinical Outlook
- Published: 11 November 2026
Nature Reviews Nephrology (2026) Cite this article
Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers (TCEs) have potential as effective desensitization therapies in highly sensitized kidney transplant candidates. Clinical utility will depend on balancing treatment-related risks against the potential survival and quality-of-life benefits of facilitated transplantation.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
32.70 € / 30 days cancel any time
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:

References
Boenink, R. et al. The ERA Registry annual report 2022: epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons. Clin. Kidney J. 18, sfae405 https://doi.org/10.1093/ckj/sfae405 (2025).
Zecher, D. et al. Impact of sensitization on waiting time prior to kidney transplantation in Germany. Transplantation 106, 2448–2455 https://doi.org/10.1097/TP.0000000000004238 (2022).
Reuter, S., Lachmann, N., de Ferrante, H., Bohmig, G. A. & Budde, K. Highly sensitized kidney transplant candidates: integrating acceptable mismatch, desensitization, imlifidase, and emerging immune-cell targeting strategies. Front. Immunol. 17, 1868642 https://doi.org/10.3389/fimmu.2026.1868642 (2026).
Lorant, T. et al. Five years follow-up of imlifidase desensitized kidney transplant recipients. Transpl. Int. 38, 15425 https://doi.org/10.3389/ti.2025.15425 (2025).
Tur, C. et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann. Rheum. Dis. 84, 106–114 https://doi.org/10.1136/ard-2024-226142 (2025).
Vandenboom, H. et al. Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis. Haematologica 111, 745–750 https://doi.org/10.3324/haematol.2025.288174 (2026).
Bhoj, V. G. et al. Kidney transplantation in two highly sensitized candidates after CAR T-cell therapy. N. Engl. J. Med. 394, 2117–2125 https://doi.org/10.1056/NEJMoa2513428 (2026).
Schrezenmeier, J. et al. Kidney transplantation after clearing anti-HLA antibodies with CD19 CAR T cells. N. Engl. J. Med. 394, 2166–2168 https://doi.org/10.1056/NEJMc2517277 (2026).
Leon, J. et al. B-cell maturation antigen-targeted T-cell engager therapy combined with B-cell depletion for treatment of refractory HLA sensitization. Kidney Int. 109, 1148–1154 https://doi.org/10.1016/j.kint.2026.01.020 (2026).
Schatzl, M. et al. T-cell engager-mediated HLA antibody depletion before kidney transplantation. N. Engl. J. Med. 395, 511–513 https://doi.org/10.1056/NEJMc2603853 (2026).
Author information
Authors and Affiliations
Department of Nephrology and Hypertension, Uniklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Louisa Steines & Mario Schiffer
Authors
- Louisa Steines
- Mario Schiffer
Corresponding authors
Correspondence to Louisa Steines or Mario Schiffer.
Ethics declarations
Competing interests
The authors declare no competing interests.
About this article
Cite this article
Steines, L., Schiffer, M. CAR T cells and T cell engagers for desensitization in kidney transplantation. Nat Rev Nephrol (2026). https://doi.org/10.1038/s41581-026-01152-3
Published: 11 November 2026
Version of record: 11 November 2026
DOI: https://doi.org/10.1038/s41581-026-01152-3
来源:Nature 健康护理主题 · nature.com